Dan Shelly
Chief Business Development Officer PolTREG
Daniel Shelly is a member of the Executive Leadership Team at PolTREG, where he leads efforts to advance next-generation T-regulatory cell therapies for autoimmune diseases. He previously served as VP of Business Development at Prescient Therapeutics, driving CAR-immune cell therapy and targeted therapy programs. With over 19 years of experience in biopharma business development and alliances, he has also held leadership roles at PATH and co-led its COVID-19 task force. He is an adjunct professor in the Clinical Drug Development program at the University of Cincinnati’s College of Pharmacy.
Seminars
Wednesday 25th March 2026
Navigating Regulatory Pathways Across Next-Generation Treg Therapies
4:30 pm
- Establishing a regulatory foundation: Unraveling the regulatory journey from EMA clinical success to the FDA
- Utilizing targeting and conditioning to enhance therapeutic efficacy in T1D CAR-Treg therapies
- Shaping the future of targeted Treg therapies with multi-edited allogenic CAR-Tregs across a broad range of indications
Wednesday 25th March 2026
Industry Leader’s Fireside Chat: Evaluating the Global Treg Landscape to Explore the Future of Space
8:40 am
- Exploring the global Treg landscape to identify emerging opportunities and the direction of future Treg development
- Exploring the interest in Treg collaboration and investment amid industry changes and recent changes in the industry
- Discussing the broad landscape of Treg therapy economics considering cost, reimbursement and tariff impacts
